Skip to main content
rss feedemail usour twitterour facebook page linkdin youtubeinstagram
Sunday, March 20 2022


Many drug companies are developing gene-based treatments for sickle cell and beta thalassemia, a related blood disorder. But Novartis and Precision say they still see a need for treatments that can work inside the body, rather than via stem cells edited in a laboratory, and can be deployed in countries where stem cell transplants can’t be easily carried out.
Read more here

Posted by: ESCF Admin AT 10:25 am   |  Permalink   |  Email